Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Maharathi Basu headshot

CDC's New Guidance Makes the Skyline Sunnier for U.S. Airlines

by Maharathi Basu

CDC's latest travel manual provides a further impetus to the U.S. airline stocks like Delta (DAL), Southwest Airlines (LUV) and American Airlines (AA), which are scaling an outstanding graph on the bourses this year.

SpringWorks (SWTX) Begins Dosing in Multiple Myeloma Study

by Zacks Equity Research

SpringWorks (SWTX) doses the first patient in a phase Ib study evaluating nirogacestat in combination with teclistamab for the treatment of relapsed or refractory multiple myeloma.

AbbVie's (ABBV) Rinvoq Dermatitis sNDA Review Gets Delayed

by Zacks Equity Research

The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in atopic dermatitis by three months.

J&J (JNJ) Gets Full Charge of Emergent COVID-19 Vaccine Plant

by Zacks Equity Research

The U.S. government places J&J (JNJ) in charge of Emergent's Baltimore factory. The facility will cease production of AstraZeneca shots.

Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo

by Zacks Equity Research

Exelixis' (EXEL) partner Ipsen secures an approval from the regulatory body in Europe for the combination of Cabomteyx and Opdivo to treat first-line RCC.

Dow, Gibraltar Industries, Pfizer, BioNTech and Micron highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Dow, Gibraltar Industries, Pfizer, BioNTech and Micron highlighted as Zacks Bull and Bear of the Day

Pfizer (PFE)/BioNTech COVID-19 Vaccine 100% Effective in Teens

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) report 100% efficacy for their COVID-19 vaccine in teenagers aged 12 to 15.

Mark Vickery headshot

Dow Dips, Other Markets Up for the Day; Micron (MU) Beats

by Mark Vickery

Micron Technologies (MU), a Zacks Rank #1 (Strong Buy) memory and data storage giant, posted a modest beat on both top and bottom lines in its fiscal Q2 earnings.

Sweta Jaiswal, FRM headshot

ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update

by Sweta Jaiswal, FRM

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.

Merck's (MRK) Breast Cancer sBLA for Keytruda Gets CRL (Revised)

by Zacks Equity Research

FDA issues a complete response letter to Merck's (MRK) sBLA seeking label expansion of Keytruda as neoadjuvant and adjuvant treatment for patients with triple-negative breast cancer. A phase III study in this indication is ongoing.

Merck (MRK) Keytruda Gets CHMP Nod for First-Line Bladder Cancer

by Zacks Equity Research

Merck (MRK) is seeking approval for label expansion of Keytruda in Europe to include first-line treatment of certain patients with advanced or metastatic urothelial carcinoma.

Sweta Jaiswal, FRM headshot

Moderna ETFs to Gain on Positive 'Real-World' Study Data

by Sweta Jaiswal, FRM

Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.

Merck's (MRK) Breast Cancer sBLA for Keytruda Gets CRL

by Zacks Equity Research

FDA issues a complete response letter to Merck's (MRK) sBLA seeking label expansion of Keytruda as neoadjuvant and adjuvant treatment for patients with triple-negative breast cancer. A phase III study in this indication is ongoing.

Pfizer (PFE) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $36.62, marking a +1.02% move from the previous day.

Thermo Fisher (TMO) Launches Surveillance Tool for COVID-19

by Zacks Equity Research

The latest launch of surveillance solution is an extremely timely development by Thermo Fisher (TMO) and is expected to witness fast market adoption.

J&J's (JNJ) Pharma Unit & COVID-19 Vaccine Key to 2021 Growth

by Zacks Equity Research

J&J's (JNJ) Pharma unit is performing above-market levels, helped by new drugs and label expansion of blockbuster drugs, Imbruvica, Darzalex & Stelara. Its COVID-19 vaccine is expected to contribute to sales growth.

David Borun headshot

Bull of the Day: Owens and Minor (OMI)

by David Borun

This medical logistics company made big gains in 2020 - and is poised to keep heading higher.

Pfizer (PFE) Gets Unfavorable Votes from FDA Panel for Tanezumab

by Zacks Equity Research

Pfizer (PFE) and Eli Lilly receive FDA Joint Advisory Committee's vote results for tanezumab being developed for treating osteoarthritis pain. The committee voted 1 in favor and 19 against tanezumab.

The Zacks Analyst Blog Highlights: Pfizer, UnitedHealth Group, Centene Corp, Cigna Corp and AMN Healthcare Services

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, UnitedHealth Group, Centene Corp, Cigna Corp and AMN Healthcare Services

AstraZeneca (AZN) Reports New Efficacy Data on COVID-19 Vaccine

by Zacks Equity Research

AstraZeneca (AZN) reports new efficacy data for its COVID-19 vaccine in the Unites States following criticism for providing outdated data.

4 Stocks That Continue to Gain From Telehealth Offerings

by Zacks Equity Research

We take a sneak peek into four telehealth stocks that are well-poised for growth on their robust digital services suite.

Myovant's (MYOV) Data on Relugolix for Uterine Fibroids Positive

by Zacks Equity Research

Myovant (MYOV) and partner Pfizer report positive data from the phase III LIBERTY study evaluating relugolix combination therapy for treating women with uterine fibroids.

Pfizer (PFE) Begins Clinical Study on COVID-19 Antiviral Pill

by Zacks Equity Research

Pfizer (PFE) starts an early-stage U.S. study on an oral COVID-19 antiviral candidate.

Merck (MRK) Gets FDA Nod for Keytruda in Esophageal Cancer

by Zacks Equity Research

The FDA approves Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy, for the first-line treatment of esophageal and gastroesophageal junction carcinoma.

Humana (HUM), Inovalon Expands Ties for Vaccine Adherence Efforts

by Zacks Equity Research

Humana (HUM) extends collaboration with Inovalon, which highlights the company's focus on vaccine adherence for helping its health plan members.